Get notified when NUVB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNuvation Bio raises $250M in convertible notes, repays $58.5M loan and funds dilution hedge
Filed June 30, 2026 · Period ending June 24, 2026 · ~1 min read
Key Changes
-
high
Priced $250M of 0.75% convertible senior notes due 2032, upsized from initially announced $200M, convertible at $7.84/share (35% premium to June 25 close).
Item 1.01 verify on EDGAR → -
high
Used proceeds to fully repay $58.5M senior secured loan (terminating March 2025 credit agreement), fund $14.9M capped call hedge, and support general operations.
Item 1.02 verify on EDGAR → -
medium
Entered capped call transactions covering shares underlying notes to reduce conversion dilution, capped at $10.46/share (80% premium to June 25 close).
Item 8.01 verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ORIB 10-K) is open in full — no account needed.
Partner
Trade NUVB commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jul 10, 2026 · How we verify